Navigation Links
Sopherion Therapeutics Announces Appointment of New Senior Executive Vice President for Clinical Affairs
Date:2/24/2009

PRINCETON, N.J., Feb. 24 /PRNewswire/ -- Sopherion Therapeutics, LLC, a biopharmaceutical company focused on the development and commercialization of anti-cancer therapies, has announced the appointment of Dr. Marcel Rozencweig as Senior Executive Vice President for Clinical Affairs. Prior to joining Sopherion, Dr. Rozencweig was a key Clinical Development Consultant to the Company and a member of the Sopherion Protocol Development Team for Myocet.

"I am excited to continue to contribute to the development of Myocet," said Dr. Rozencweig. "Myocet has the potential to be a valued addition to the first-line treatment regimen for metastatic breast cancer, particularly in patients with HER-2 overexpression."

Dr. Rozencweig was previously with GPC-Biotech since 2001. He has 18 years of experience with Bristol-Myers Squibb, where he held several senior leadership positions in drug development and strategic planning, including Vice President, Oncology, Infectious Diseases and Immunology Clinical Research; and Vice President, Strategic Planning and Portfolio Management.

"Dr. Rozencweig's world-renowned experience in oncology drug development is an ideal fit for Sopherion as we move Myocet forward," said Ronald H. Goldfarb, Ph.D., President and CEO of Sopherion Therapeutics. "His many achievements include significant contributions leading to the FDA approval of 11 drugs, mostly anticancer treatments, including the blockbusters Taxol(R) and Paraplatin(R) (carboplatin)."

Dr. Rozencweig is an Adjunct Associate Professor of Medicine at New York University and has authored or co-authored more than 200 scientific publications.

About Sopherion Therapeutics, LLC

Sopherion Therapeutics, LLC is a privately-held biotechnology company based in Princeton, New Jersey. The Company is focused on developing novel anti-cancer therapies for patients suffering with advanced cancer, particularly metastatic disease. Sopherion is dedicated to the acquisition, discovery, development and commercialization of novel anti-cancer therapies with unique therapeutic activities that address unmet medical needs in and extend human life. In 2004, Sopherion entered into an exclusive licensing agreement with Zeneus Pharma Ltd., now Cephalon, Inc. for the future commercialization of Myocet in North America. For more information, visit www.sopherion.com.


'/>"/>
SOURCE Sopherion Therapeutics, LLC
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Cell Therapeutics to Resume Trading on MTA and NASDAQ
2. United Therapeutics Reports 2008 Fourth Quarter and Annual Financial Results
3. Cell Therapeutics Updates Shareholders on Trading
4. Transition Therapeutics Announces Second Quarter Fiscal 2009 Financial Results
5. Arete Therapeutics Initiates Phase IIa Clinical Trial for AR9281, a Novel s-EH Inhibitor to Treat Type 2 Diabetes
6. Transition Therapeutics to Hold Conference Call on Second Quarter Fiscal 2009 Financial Results on Wednesday, February 11th, at 4:30 P.M. EST
7. Transition Therapeutics Announces Completion of Patient Enrolment of Phase 2 Study of TT-223 in Type 2 Diabetes Patients
8. Nile Therapeutics to Present at the 2009 BIO CEO & Investor Conference
9. Nile Therapeutics to Present at the 27th Annual J.P. Morgan Healthcare Conference
10. Merck Serono and Apitope Announce Licensing Agreement on Novel Peptide Therapeutics for the Treatment of Multiple Sclerosis
11. AHRQ Announces New Web Site on Emerging Issues in Medical Therapeutics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... Wallingford, CT (PRWEB) , ... March 28, 2017 ... ... hemostatic devices, announces today that the University of Pittsburgh Medical Center (UPMC) will ... Central and Western Pennsylvania. , The program, developed in association with efforts by ...
(Date:3/28/2017)... (PRWEB) , ... March 28, 2017 , ... Usually, the ... the daily wardrobe. However, for those self-conscious about a double chin, this means more ... the ideal solution. , “For most people, a double chin is undesirable,” Dr. ...
(Date:3/28/2017)... ... March 28, 2017 , ... Calibration, ... to ensuring high-quality results and maintaining GMP and USP compliance. In a new ... accordance with GMP requirements " these requirements are explained. The challenge is ...
(Date:3/28/2017)... (PRWEB) , ... March 28, 2017 , ... ... in Wethersfield, Conn., has relocated its corporate headquarters to a new, more expansive ... , In October 2016, Qualidigm purchased a distressed office building in Wethersfield, ...
(Date:3/28/2017)... ... March 28, 2017 , ... With less than 10,000 dermatologists in the United ... can be limited while the desire to conquer breakouts and eliminate skincare stress is ... every customer online, today released its inaugural survey on the State of Acne in ...
Breaking Medicine News(10 mins):
(Date:3/27/2017)... LightIntegra Technology Inc. today announced that its ... President and Chief Executive Officer effective March 13, 2017. ... Directors of LightIntegra. Paul Geyer will continue ... "This is the perfect time for Bill ... We,ve selected a very strong leader at a time ...
(Date:3/27/2017)... 2017  Sanderling Ventures, portfolio company, Torax Medical, ... of Johnson & Johnson. Torax manufactures and markets the ... gastro-esophageal reflux disease (GERD). The LINK device is ... the procedure is currently available in the U.S. ... was founded by Sanderling Ventures, Mayo Medical Ventures ...
(Date:3/27/2017)... March 27, 2017 FinancialBuzz.com News Commentary  ... Based on New Frontier ... states where cannabis is legal will generate $655 million in taxes ... from cannabis specific taxes, such as Washington State,s ... be earned from state sales taxes that are applied on all ...
Breaking Medicine Technology: